Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FASTNET TO FARM IN TO TENDRARA LAKBIR

29 May 2013 07:00

RNS Number : 7384F
Fastnet Oil & Gas PLC
29 May 2013
 



29 May 2013

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

FASTNET EXECUTES EXCLUSIVE OPTION AGREEMENT TO FARM INTO THE TENDRARA LAKBIR PETROLEUM AGREEMENT ONSHORE MOROCCO

 

Highlights

 

§ Highly prospective acreage covering 14,548 sq. km.

§ Existing gas discoveries in Triassic Tagi reservoirs most of them are within Essaouira onshore

§ Proven hydrocarbon system

§ Exclusive Option Agreement with low entry cost

§ Earn-in appraisal/pre-development well planned for late 2013/early 2014

§ Gross interest of 50% (net interest 37.5% after including the ONHYM carry through exploration of 25%)¹after earn-in well and receipt of regulatory approvals

§ Partially de-risked Tendrara Lakbir has been independently assessed as having an important potential of gas

§ Partnership with a local exploration company OGIF

 

Fastnet (AIM: FAST, ESM: FOI) the listed E&P company focused on near term exploration acreage in Morocco and the Celtic Sea, is pleased to announce that its wholly owned subsidiary Pathfinder Hydrocarbon Ventures Limited ("Pathfinder") has executed an exclusive option agreement (the "Option Agreement") with Oil and Gas Investments Funds ("OGIF") to farm into eight Exploration Blocks comprising the Tendrara Lakbir Petroleum Agreement (the "Tendrara Lakbir Licence" or the "Licence Area") onshore Morocco (see map of the area on the Company's website: http://www.fastnetoilandgas.com/operations/morocco.aspx).

 

The Tendrara Lakbir Licence covers an area of 14,548 sq. km. It covers the majority of the Tendrara Basin, which lies between the Middle Atlas to the north and the High Atlas to the south and which is one of Morocco's prospective basins for Triassic gas. Five wells drilled within the Licence Area have encountered gas-bearing Triassic sands of the Tagi Formation (the "Tagi"). The Tagi is the host reservoir for Morocco's producing Meskala gas field, along strike to the west in the Essaouira Basin. All these gas discoveries have been charged from the prolific Silurian source rocks that are an integral part of the proven Palaeozoic-Early Mesozoic petroleum systems covering large parts of Libya, Algeria and Morocco.

 

The key terms of the Option Agreement with OGIF are as follows:

 

§ Exclusive Option Agreement

§ Entrance Fee payable to OGIF of USD 300,000

§ Pay 100% of the cost to drill, test and complete an appraisal/pre-development well on the TE-5 Structure (which is where the last well was drilled in the License Area) - the well to be drilled on or before 28 February 2014

§ Pathfinder to put together an Outline Plan of Development for the TE-5 gas discovery

§ Pathfinder shall act as Technical Operator for the drilling of the well

§ Upon completion of the well OGIF shall transfer on or before 30 September 2014 a Gross interest of 50% (a net interest of 37.5% after including the ONHYM carry through exploration of 25%)¹ in the Tendrara Lakbir Licence to Pathfinder and Pathfinder shall assume the operatorship under the terms of the Petroleum Agreement and Association Contract, subject to all regulatory approvals being received

§ Upon the successful completion of the well and the closing of the transfer of equity interest in the Tendrara Licence, Pathfinder shall provide OGIF with a USD 2.75 mm irrevocable bank guarantee, in the event Pathfinder withdraws from the Tendrara Licence, or which shall be returned to Pathfinder by OGIF upon completion of a further work programme whereby Pathfinder shall pay the costs of drilling two additional appraisal/pre-development wells by 1st April 2015 and 1st April 2018

 

1 The gross ONHYM carry on all Moroccan exploration licences is 25%.

 

The TE-5 gas discovery was made in 2006 in the Tendrara Licence. Petrophysical reservoir parameters were the best seen in the Tendrara Licence and comparable to those of the producing Meskala gas field. The well was re-entered and put on an extended well test in 2008 and encouragingly no significant pressure depletion was recorded. However the well failed to reach its optimum predicted deliverability rate of 4 to 7 MMCFD for the reservoir parameters verified by earlier log analysis. A number of promising pay zones were not perforated.

 

The TE-5 Structure has 3D seismic coverage which has been more fully interpreted following the 2008 testing programme. It shows a significant seismic anomaly in the Tagi northeast of the well which has been interpreted as indicating the presence of more favourable reservoir properties. It is this area that will be targeted by Pathfinder in the appraisal/pre-development well.

 

OGIF commissioned third party studies in 2011 following the TE-5 (Structure) extended well test and 3D seismic interpretation that indicates an important potential of gas.

 

Pathfinder's appraisal/pre-development well will be designed to firstly: narrow the range in GIIP by better well and 3D seismic correlation of reservoir attributes; and secondly to optimise potential well deliverabilities for input into an Outline Plan of Development.

 

The Tendrara Licence contains a large number of Tagi gas discoveries, prospects and leads with additional, as yet untested, potential in Palaeozoic formations.

 

If the drilling results are positive, there are opportunities either to export through the Maghreb gas pipeline; to supply power indirectly through the Ain Beni Mathar Power Plant; or directly through on-site power generation. OGIF is a local exploration company which has already done a lot of work and is a valuable partner to develop the area.

 

 

 

Paul Griffiths, Managing Director of Fastnet said:

 

"Subject to fulfilling our drilling commitment and regulatory approvals, we will be increasing our acreage position in Morocco. The Tendrara Licence offers our shareholders an exciting early drilling opportunity to appraise an existing gas discovery. Fastnet has sourced a rig for the upcoming Tendrara drilling operations. A successful drilling result at Tendrara could be the catalyst to move towards an Outline Development Plan and rapid monetisation of the original gas discovery. In this respect OGIF is a particularly valued partner as we share a common vision of being a joint venture partnership with ONHYM capable of making a material impact on the Moroccan gas market and assisting the drive for gas-fired power generation. It's a further example of Fastnet's management team's activity driven ethos which we believe creates greater potential to generate near-term shareholder value"

 

 

 

For further information please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

Mirabaud Securities LLP

(Joint Broker)

Peter Krens, Edward Haig-Thomas

 

 

+44 (20) 7321 2508

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

+353 (1) 679 6363

FTI Consulting

Natalia Erikssen, Nicola Murray

+44 (0) 207 831 3113

 

Notes to editors

Fastnet Oil & Gas plc is an independent oil and gas exploration company that focuses on identifying early stage exploration and appraisal opportunities in Offshore Ireland and Africa. It is quoted on the AIM market of the London Stock Exchange and the Enterprise Securities Market (ESM) of the Irish Stock Exchange. Fastnet's aim is to assemble a portfolio of high impact conventional oil and gas assets that will deliver sustainable growth and value for the Company. Its immediate focus is on implementing its Offshore Ireland and Africa strategies where it has been awarded four offshore licensing options in the Celtic Sea (Molly Malone Basin, Shanagarry, 49/13 and Mizzen Basin) and acquired a material interest in the Foum Assaka permit Offshore Morocco. In addition, Fastnet will continue to pursue new conventional oil and gas opportunities in Africa where the Directors and Advisory Board also have extensive knowledge, contacts and experience of creating value.

 

 This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFVDEAITFIV
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.